文献速递神经免疫

住院治疗的感染与多发性硬化残疾加重的风险

Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis.
PubMed 文献 · Ann Neurol · 2024-07-10

这项队列研究利用瑞典多发性硬化登记库2000至2021年数据,纳入8,759个利妥昔单抗和7,561个干扰素β/醋酸格拉替雷治疗 episodes,发现利妥昔单抗较干扰素β/醋酸格拉替雷增加感染风险(住院HR 2.08,门诊HR 1.37),但住院感染后残疾加重风险在干扰素β/醋酸格拉替雷组更高(HR 2.01),利妥昔单抗组未观察到。

要点

  • 利妥昔单抗较干扰素β/醋酸格拉替雷增加住院感染风险(HR 2.08)和门诊感染风险(HR 1.37)。
  • 住院感染与EDSS增加0.19单位相关(95%CI 0.12-0.26)。
  • 控制复发和MRI活动后,住院感染与干扰素β/醋酸格拉替雷组残疾加重相关(HR 2.01),利妥昔单抗组未观察到。

核心结论

  • 与干扰素β/醋酸格拉替雷相比,利妥昔单抗使感染风险加倍,但降低后续残疾加重风险。
  • 住院感染后残疾加重风险在进展型多发性硬化中高于复发缓解型。
  • 应考虑感染风险以改善长期结局。

研究设计与样本

  • 这项队列研究从2000年至2021年,使用瑞典多发性硬化登记库链接国家医疗登记数据,包含8,759个利妥昔单抗和7,561个干扰素β/醋酸格拉替雷治疗 episodes。
  • 使用多变量Cox模型估计住院治疗感染风险,使用双重稳健广义估计方程模型评估感染与EDSS评分增加的相关性,并使用分段指数模型分析超过定义切点值的残疾加重事件,控制复发和MRI活动。

主要发现

  • 与干扰素β/醋酸格拉替雷相比,利妥昔单抗显示住院治疗感染风险增加(HR 2.08;95%CI 1.50-2.90)和门诊治疗感染风险增加(HR 1.37;95%CI 1.13-1.67)。
  • 住院治疗感染与EDSS增加0.19单位相关(95%CI 0.12-0.26)。
  • 残疾加重程度在进展型多发性硬化中最大,且在干扰素β/醋酸格拉替雷治疗下(与利妥昔单抗不同)更常与MRI活动相关。
  • 控制复发和MRI活动后,住院治疗感染与接受干扰素β/醋酸格拉替雷治疗的复发缓解型多发性硬化患者残疾加重相关(HR 2.01;95%CI 1.59-2.53),但在接受利妥昔单抗治疗的患者中不相关。

临床怎么用

  • 原文结论指出应考虑感染风险以改善长期结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the association between infections and disability worsening in people with multiple sclerosis (MS) treated with either B-cell depleting therapy (rituximab) or interferon-beta/glatiramer acetate (IFN/GA). METHODS: This cohort study spanned from 2000 to 2021, using data from the Swedish MS Registry linked to national health care registries, comprising 8,759 rituximab and 7,561 IFN/GA treatment episodes. The risk of hospital-treated infection was estimated using multivariable Cox models. The association between infections and increase in Expanded Disability Status Scale (EDSS) scores was assessed using a doubly robust generalized estimating equations model. Additionally, a piece-wise exponential model analyzed events of increased disability beyond defined cut-off values, controlling for relapses, and MRI activity. RESULTS: Compared with IFN/GA, rituximab displayed increased risk of both inpatient- and outpatient-treated infections (hazard ratio [HR], 2.08; 95% confidence interval [CI], 1.50-2.90 and HR, 1.37; 95% CI, 1.13-1.67, respectively). An inpatient-treated infection was associated with a 0.19-unit increase in EDSS (95% CI, 0.12-0.26). Degree of worsening was greatest for progressive MS, and under IFN/GA treatment, which unlike rituximab, was more commonly associated with MRI activity. After controlling for relapses and MRI activity, inpatient-treated infections were associated with disability worsening in people with relapsing-remitting MS treated with IFN/GA (HR, 2.01; 95% CI, 1.59-2.53), but not in those treated with rituximab. INTERPRETATION: Compared to IFN/GA, rituximab doubled the infection risk, but reduced the risk of subsequent disability worsening. Further, the risk of worsening after hospital-treated infection was greater with progressive MS than with relapsing-remitting MS. Infection risk should be considered to improve long term outcomes. ANN NEUROL 2024;96:694-703.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Hu Y, Frisell T, Alping P, et al. Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis. Ann Neurol. 2024. PMID: 38984615. doi:10.1002/ana.27026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。